Roxicodone 15mg – The Complete Medical Guide
Roxicodone 15mg is an immediate-release oxycodone tablet classified as a Schedule II controlled substance. This intermediate-strength formulation is prescribed for moderate to severe acute pain in opioid-tolerant patients. As a pure oxycodone product (without acetaminophen), it carries significant risks of misuse, addiction, and respiratory depression.
Roxicodone 15mg
Roxicodone 15mg is a prescription opioid pain medication used to manage moderate to severe pain. It contains 15mg of oxycodone, a potent narcotic that works by altering the way the brain and nervous system perceive pain. Roxicodone provides fast-acting pain relief, making it ideal for short-term pain management or breakthrough pain. Due to its strength, it should be used only as prescribed by a healthcare provider to avoid risks such as misuse, addiction, or overdose. Always follow your doctor’s guidelines for safe and effective use of Roxicodone 15mg.
Medical Uses & Indications
FDA-Approved Uses
Moderate to severe acute pain requiring opioid analgesia
Breakthrough cancer pain in opioid-tolerant patients
Postoperative pain management
Trauma-related pain
Key Clinical Features
• Formulation: Immediate-release (no abuse-deterrent properties)
• Onset: 15-30 minutes
• Duration: 4-6 hours
• Equianalgesic ratio: 15mg ≈ 22.5mg oral morphine
• DEA Classification: Schedule II (Highest abuse potential)
Pharmacology & Mechanism
Neurochemical Action
• Full μ-opioid receptor agonist
• κ-opioid receptor partial agonist
• Inhibits ascending pain pathways
Metabolic Profile
• Hepatic metabolism: CYP3A4 (major), CYP2D6 (minor)
• Active metabolite: Oxymorphone (via CYP2D6)
• Elimination half-life: 3-5 hours
Dosing & Administration
Standard Protocol
• Opioid-tolerant adults: 10-15mg every 4-6 hours as needed
• Maximum initial daily dose: 60mg
Conversion Guidelines
| Current Opioid | Roxicodone 15mg Equivalent |
|---|---|
| Morphine 22.5mg PO | 15mg |
| Hydrocodone 15mg | 15mg |
| Oxycodone CR 30mg daily | 15mg q12h |
Critical Safety Notes
Not for opioid-naïve patients
Never crush/chew tablets (dose dumping risk)
Naloxone co-prescription mandatory
Daily PDMP monitoring recommended
Safety Profile
Common Adverse Effects
• Constipation (prophylaxis required)
• Nausea/vomiting (30-40%)
• Dizziness/sedation
• Pruritus (20-25%)
Black Box Warnings
High potential for addiction and abuse
Life-threatening respiratory depression
Accidental ingestion danger
Neonatal opioid withdrawal syndrome
Risk Mitigation Strategies
Prescribing Safeguards
-
Limit to 3-5 day supply for acute pain
-
State PDMP review before each prescription
-
Written treatment agreement
-
Frequent follow-up assessments
Patient Education
• Never share medication
• Recognize overdose signs
• Proper storage/disposal
• Avoid all CNS depressants
Clinical Alternatives
For Moderate-Severe Pain
• Oxycodone/acetaminophen combinations
• Hydrocodone immediate-release
• Morphine sulfate IR
Non-Opioid Options
• Ketorolac limited course
• Diclofenac sodium
• Lidocaine patches
Special Population Considerations
| Population | Dosing Adjustment | Monitoring |
|---|---|---|
| Elderly (≥65) | Start with 5-7.5mg | Increased fall risk |
| Hepatic impairment | 50% dose reduction | LFT monitoring |
| Renal (CrCl<30) | Extended interval (q8h) | Renal function |
| Pediatric | CONTRAINDICATED | – |